Organon & Co. (NYSE:OGN – Get Free Report) announced a quarterly dividend on Friday, July 31st. Stockholders of record on Friday, August 14th will be given a dividend of 0.02 per share on Thursday, September 10th. This represents a c) dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th.
Organon & Co. has a payout ratio of 2.0% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Organon & Co. to earn $3.44 per share next year, which means the company should continue to be able to cover its $0.08 annual dividend with an expected future payout ratio of 2.3%.
Organon & Co. Stock Up 0.0%
Shares of NYSE OGN opened at $13.55 on Friday. The stock has a market cap of $3.56 billion, a PE ratio of 14.58, a price-to-earnings-growth ratio of 1.25 and a beta of 1.54. The company has a quick ratio of 1.42, a current ratio of 1.97 and a debt-to-equity ratio of 9.47. Organon & Co. has a 52-week low of $5.69 and a 52-week high of $13.60. The business has a 50-day moving average price of $13.47 and a 200 day moving average price of $10.40.
Analysts Set New Price Targets
Several research analysts have issued reports on the stock. BNP Paribas Exane reissued a “neutral” rating and set a $14.00 price objective (up from $12.00) on shares of Organon & Co. in a research report on Wednesday, April 29th. Zacks Research raised Organon & Co. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 14th. Piper Sandler upgraded Organon & Co. from an “underweight” rating to a “neutral” rating and lifted their target price for the company from $5.00 to $14.00 in a research note on Tuesday, April 28th. Finally, Weiss Ratings upgraded shares of Organon & Co. from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, July 13th. Five research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Reduce” and a consensus price target of $11.40.
Check Out Our Latest Stock Analysis on Organon & Co.
Organon & Co. Company Profile
Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.
In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.
Further Reading
- Five stocks we like better than Organon & Co.
- Lost in Space: Why Aerospace Valuations Are Plummeting Right Now
- MarketBeat Week in Review – 07/27- 07/31
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.
